SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am. 2005; 34: 235245.
  • 2
    Talley NJ, Phillips SF, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut. 1990; 31: 7781.
  • 3
    Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997; 11: 315.
  • 4
    Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996; 91: 927934.
  • 5
    Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocytic protein calprotectin. J Clin Pathol Mol Pathol. 1997; 50: 113123.
  • 6
    Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol. 1994; 32: 26292630.
  • 7
    Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000; 47: 506513.
  • 8
    Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003; 98: 13091314.
    Direct Link:
  • 9
    Vernier G, Sendid B, Poulain D, et al. Relevance of serologic studies in inflammatory bowel disease. Curr Gastroenterol Rep. 2004; 6: 482487.
  • 10
    Heelan BT, Allan S, Barnes RM. Identification of a 200-kDa glycoprotein antigen of Saccharomyces cerevisiae. Immunol Lett. 1991; 28: 181185.
  • 11
    Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohns disease. Clin Diagn Lab Immunol. 1996; 3: 219226.
  • 12
    Terjung B, Worman HJ, Herzog V, et al. Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol. 2001; 126: 3746.
  • 13
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979; 77: 843846.
  • 14
    Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60: 505512.
  • 15
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 16251629.
  • 16
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989; 298: 8286.
  • 17
    Seibold F, Stich O, Hufnagl R, et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol. 2001; 36: 196201.
  • 18
    Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut. 1992; 33: 657662.
  • 19
    Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33: 1422.
  • 20
    Summerton CD, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002; 14: 841845.
  • 21
    Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005; 51: 117126.
  • 22
    Schoepfer AM, Trummler M, Seeholzer P, et al. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007 (in press).
  • 23
    D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007; 22: 429437.
  • 24
    Scerpella EG, Okhuysen PC, Mathewson JJ, et al. Evaluation of a new latex agglutination test for fecal lactoferrin in travelers' diarrhea. J Travel Med. 1994; 1: 6871.
  • 25
    Choi SW, Park CH, Silva TM, et al. To culture or not to culture: fecal lactoferrin screening for inflammatory bacterial diarrhea. J Clin Microbiol. 1996; 34: 928932.
  • 26
    Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta. 1985; 148: 105109.
  • 27
    Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002; 14: 409412.
  • 28
    Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmatic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001; 96: 730734.
    Direct Link:
  • 29
    Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998; 42: 788791.
  • 30
    Seibold F, Stich O, Hufnagl R, et al. Anti-Saccharomyces cerevisiase antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol. 2001; 36: 196201.
  • 31
    Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut. 1992; 33: 657662.
  • 32
    Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990; 86: 202210.
  • 33
    Terjung B. Anti-neutrophil antibodies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2001; 15: 629642.
  • 34
    Spiller R, Aziz Q, Creed F, et al. Guidelines for the management of irritable bowel syndrome. Gut. 2007 (in press).
  • 35
    Poullis A, Foster R, Mendall MA, et al. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003; 18: 756762.
  • 36
    Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002; 123: 450460.